N/A
N=12
Vinegar Co-ingestion in Type 2 Diabetes
Type 2 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT01279317 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Oct 2011
Primary outcome: Primary: Postprandial Glycemic Incremental Area Under the Curve — 739; 759 mmol/L / 2hr
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- placebo co-ingestion (Dietary_supplement); vinegar co-ingestion (Dietary_supplement)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- Male
- Sponsor
- Maastricht University Medical Center
- Primary completion
- Mar 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postprandial Glycemic Incremental Area Under the Curve |
739; 759 | — |
Summary
The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.
Eligibility Criteria
Inclusion Criteria
- male type 2 diabetes
- overweight or obese
- 40-70 yrs
Exclusion Criteria
- incident cardiovascular events during last year
- peptic ulcer, duodenal ulcer, oesophageal reflux
- antacids, H2 receptor blocker, proton pump inhibitors, NSAIDS, prokinetic agents
Data sourced from ClinicalTrials.gov (NCT01279317). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.